Kento Fujiwara
Overview
Explore the profile of Kento Fujiwara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fujiwara K, Kitaura M, Tsunei A, Kusabuka H, Ogaki E, Okada N
Int J Mol Sci
. 2021 Apr;
22(5).
PMID: 33804441
T cells that are genetically engineered to express chimeric antigen receptor (CAR) have a strong potential to eliminate tumor cells, yet the CAR-T cells may also induce severe side effects...
2.
Fujiwara K, Sasawatari S, Nakai S, Imaeda K, Nagai S, Matsuno Y, et al.
Cancers (Basel)
. 2020 Sep;
12(10).
PMID: 32977646
Soft tissue sarcomas (STSs) are heterogeneous and aggressive malignancies with few effective therapies available. We have developed T cells expressing a vascular endothelial growth factor receptor 2 (VEGFR2)-specific chimeric antigen...
3.
Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N
Cells
. 2020 May;
9(5).
PMID: 32397414
Chimeric antigen receptor (CAR)-T cells have demonstrated significant clinical potential; however, their strong antitumor activity may cause severe adverse effects. To ensure efficacy and safe CAR-T cell therapy, it is...
4.
Fujiwara K, Shigematsu K, Tachibana M, Okada N
IUBMB Life
. 2020 Apr;
72(8):1649-1658.
PMID: 32255257
Adoptive cell therapy using patients' own T-cells is expected to be an ideal cancer treatment strategy with excellent antitumor effects and low side effects. However, this therapy targeting solid tumors...
5.
Fujiwara K, Masutani M, Tachibana M, Okada N
Biochem Biophys Res Commun
. 2020 Mar;
527(2):350-357.
PMID: 32216966
Gene-modifying T cells expressing chimeric antigen receptor (CAR) with an extracellular domain consisting of single chain variable fragment (scFv) and an intracellular domain with a T cell activation motif, are...
6.
Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, et al.
Mol Ther Oncolytics
. 2016 Dec;
3:16024.
PMID: 27909701
We previously reported that tumor vessel-redirected T cells, which were genetically engineered with chimeric antigen receptor (CAR) specific for vascular endothelial growth factor receptor 2 (VEGFR2), demonstrated significant antitumor effects...
7.
Kusabuka H, Fujiwara K, Tokunaga Y, Hirobe S, Nakagawa S, Okada N
Biochem Biophys Res Commun
. 2016 Mar;
473(1):73-79.
PMID: 26993168
Adoptive immunotherapy using chimeric antigen receptor-expressing T (CAR-T) cells has attracted attention as an efficacious strategy for cancer treatment. To prove the efficacy and safety of CAR-T cell therapy, the...